ABVC BioPharma Inc
ABVC
Company Profile
Business description
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Contact
44370 Old Warm Springs Boulevard
FremontCA94538
USAT: +1 510 668-0881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,849.30 | 74.60 | -0.84% |
| CAC 40 | 8,104.33 | 13.45 | -0.17% |
| DAX 40 | 25,454.79 | 13.98 | 0.05% |
| Dow JONES (US) | 52,421.20 | 152.09 | -0.29% |
| FTSE 100 | 10,667.99 | 29.58 | -0.28% |
| HKSE | 24,667.24 | 250.36 | -1.00% |
| NASDAQ | 26,186.41 | 146.62 | -0.56% |
| Nikkei 225 | 63,484.10 | 8.89 | -0.01% |
| NZX 50 Index | 13,484.22 | 76.47 | -0.56% |
| S&P 500 | 7,619.98 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,672.50 | 77.40 | -0.88% |
| SSE Composite Index | 3,864.28 | 21.05 | -0.54% |